Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon, Asuragen Ink Deal to Offer microRNA PCR-based Services

NEW YORK (GenomeWeb News) – Exiqon and Asuragen announced today the signing of a service center agreement allowing Asuragen to offer real-time PCR services based on Exiqon's miRcury LNA Universal RT-microRNA PCR products.

Exiqon's technology is used for discovering new biomarkers of diseases and biological processes and combines Universal RT reaction with LNA-enhanced PCR primers. Asuragen Genomic Services Division provides nucleic acid-based services, including biomarker discovery and companion diagnostic development.

Financial and other terms of the deal were not disclosed.

"Exiqon's high-quality microRNA PCR products allow us to further expand our service offerings to meet the needs of our pharmaceutical and diagnostic partners," Carol Berry, SVP and GM of Asuragen Genomic Services Division, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.